Base de dados : MEDLINE
Pesquisa : D03.132.327.412.250.500 [Categoria DeCS]
Referências encontradas : 500 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 50 ir para página                         

  1 / 500 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23565878
[Ti] Título:Drugs to treat Alzheimer's disease.
[So] Source:J Psychosoc Nurs Ment Health Serv;51(4):11-2, 2013 Apr.
[Is] ISSN:0279-3695
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doença de Alzheimer/tratamento farmacológico
Doença de Alzheimer/enfermagem
Nootrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Contraindicações
Mesilatos Ergoloides/efeitos adversos
Mesilatos Ergoloides/uso terapêutico
Seres Humanos
Isoxsuprina/efeitos adversos
Isoxsuprina/uso terapêutico
Memantina/efeitos adversos
Memantina/uso terapêutico
Nootrópicos/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nootropic Agents); 8067-24-1 (Ergoloid Mesylates); R15UI3245N (Isoxsuprine); W8O17SJF3T (Memantine)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:130410
[St] Status:MEDLINE
[do] DOI:10.3928/02793695-20130306-99


  2 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19504748
[Au] Autor:Yu C; Meng J; Chen J; Tang X
[Ad] Endereço:Department of Pharmaceutics, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China.
[Ti] Título:Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity.
[So] Source:Int J Pharm;375(1-2):16-21, 2009 Jun 22.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of this investigation was to prepare ergoloid mesylate submicron emulsions (EMSEs) for enhancing nasal absorption of drug and reducing nasal ciliotoxicity. Following intranasal administrations of EMSE and ergoloid mesylate solution (EMS) and intravenous administration of EMS to rats separately at the dose of 2 mg kg(-1), the levels of EM in blood and the cerebrospinal fluid (CSF) were evaluated by microdialysis method. The nasal ciliotoxicity was evaluated by using in situ toad palate model. The absolute bioavailability and the AUC in the CSF following intranasal administration of EMSE (56.3 +/- 5.3%, AUC(CSF) 28,594 +/- 5680 ng ml(-1) min) were statistically higher than those after intranasal administration of EMS (47.4 +/- 3.5%, AUC(CSF) 19,870 +/- 2247 ng ml(-1) min). No significant difference was found for the value of the brain drug direct transport percentage (DTP%) or the drug targeting efficiency (DTE) between the group receiving EMSE and the group receiving EMS. In conclusion, EMSE exhibited higher nasal absorption of EM in rats and significantly lower nasal ciliotoxicity whereas no greater brain-targeting efficiency in comparison with EMS.
[Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos
Mesilatos Ergoloides/farmacocinética
Mucosa Nasal/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Anuros
Área Sob a Curva
Disponibilidade Biológica
Transporte Biológico
Encéfalo/metabolismo
Cílios/efeitos dos fármacos
Cílios/metabolismo
Emulsões
Mesilatos Ergoloides/administração & dosagem
Masculino
Microdiálise
Mucosa Nasal/metabolismo
Palato/efeitos dos fármacos
Palato/metabolismo
Ratos
Ratos Sprague-Dawley
Testes de Toxicidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Emulsions); 8067-24-1 (Ergoloid Mesylates)
[Em] Mês de entrada:0908
[Cu] Atualização por classe:090605
[Lr] Data última revisão:
090605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090609
[St] Status:MEDLINE


  3 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19437925
[Ti] Título:Drugs to treat Alzheimer's disease.
[So] Source:J Psychosoc Nurs Ment Health Serv;47(4):13-4, 2009 Apr.
[Is] ISSN:0279-3695
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doença de Alzheimer/tratamento farmacológico
Fármacos do Sistema Nervoso Central/uso terapêutico
[Mh] Termos MeSH secundário: Fármacos do Sistema Nervoso Central/efeitos adversos
Inibidores da Colinesterase/efeitos adversos
Inibidores da Colinesterase/uso terapêutico
Contraindicações
Mesilatos Ergoloides/efeitos adversos
Mesilatos Ergoloides/uso terapêutico
Seres Humanos
Isoxsuprina/efeitos adversos
Isoxsuprina/uso terapêutico
Memantina/efeitos adversos
Memantina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Agents); 0 (Cholinesterase Inhibitors); 8067-24-1 (Ergoloid Mesylates); R15UI3245N (Isoxsuprine); W8O17SJF3T (Memantine)
[Em] Mês de entrada:0907
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:090515
[St] Status:MEDLINE


  4 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17945473
[Au] Autor:Chen J; Wang X; Wang J; Liu G; Tang X
[Ad] Endereço:Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
[Ti] Título:Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats.
[So] Source:Eur J Pharm Biopharm;68(3):694-700, 2008 Mar.
[Is] ISSN:0939-6411
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to quantify the nasal delivery of ergoloid mesylate (EM) to the brain by comparing cerebrospinal fluid (CSF) and plasma EM levels after nasal administration at a dose of 4 mg/kg with those after intravenous administration. Following nasal delivery, EM reached a Cmax value (mean+/-SD) in plasma of 348.41+/-19.47 ng/ml and in CSF of 87.35+/-6.37 ng/ml after 107 and 20 min, respectively, while after intravenous injection, EM reached a Cmax value (mean+/-S.D.) in CSF of 54.81+/-4.92 ng/ml at 60 min and the Cmax in plasma was 1255.51+/-133.59 ng/ml. The AUC(CSF)/AUC plasma ratio (0.48+/-0.05) after intranasal delivery differed greatly from the ratio (0.14+/-0.04) observed after intravenous injection (P<0.05). The further analyzed data demonstrated a statistically significant distribution advantage of EM to the brain via the nasal route, and further suggesting that nasal administration can be a promising alternative for EM that undergoes first-pass metabolism following oral administration.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Mesilatos Ergoloides/administração & dosagem
Microdiálise/métodos
Cavidade Nasal/metabolismo
[Mh] Termos MeSH secundário: Animais
Barreira Hematoencefálica
Mesilatos Ergoloides/farmacocinética
Masculino
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8067-24-1 (Ergoloid Mesylates)
[Em] Mês de entrada:0806
[Cu] Atualização por classe:080310
[Lr] Data última revisão:
080310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:071020
[St] Status:MEDLINE


  5 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17941060
[Au] Autor:Bicalho B; Giolo JM; Lilla S; De Nucci G
[Ad] Endereço:Department of Pharmacology, Faculty of Medical Sciences, UNICAMP, PO BOX 6111, 13084-971, Campinas - SP, Brazil.
[Ti] Título:Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.
[So] Source:Biopharm Drug Dispos;29(1):17-28, 2008 Jan.
[Is] ISSN:0142-2782
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dihydroergotoxine is a mixture of semi-synthetic ergot alkaloids mainly used for age-related cognitive impairment. In this study, dihydroergotoxine (30 microM) was added to incubates of rat and bovine liver microsomes, and the resulting major metabolites were identified as hydroxy-dihydroergocornine, hydroxy-dihydroergocryptine and hydroxy-dihydroergocristine on the basis of molecular mass measurements, determined with a time-of-flight mass spectrometer. The relevance of these to humans was then investigated by simultaneously monitoring dihydroergotoxine and its hydroxy-metabolites in human plasma by LC-MS/MS after oral dosing of dihydroergotoxine mesylate (27 mg) to a healthy volunteer (male, age 45, height 1.93 m, weight 103 kg). In this preliminary approach, the peaks (C(max)) of dihydroergocornine, dihydroergocryptine and dihydroergocristine were about 0.04 microg/l. The peaks (C(max)) of their hydroxy-metabolites were 0.98, 0.53 and 0.30 microg/l, respectively. In conclusion, in this preliminary approach it was found that hydroxy-dihydroergocornine, hydroxy-dihydroergocryptine and hydroxy-dihydroergocristine were one order of magnitude higher in concentration than their parents in human plasma.
[Mh] Termos MeSH primário: Mesilatos Ergoloides/farmacocinética
Fígado/metabolismo
Microssomos Hepáticos/metabolismo
[Mh] Termos MeSH secundário: Administração Oral
Animais
Área Sob a Curva
Bovinos
Cromatografia Líquida de Alta Pressão
Cromatografia Líquida
Di-Hidroergocornina/química
Di-Hidroergocornina/metabolismo
Di-Hidroergocristina/química
Di-Hidroergocristina/metabolismo
Di-Hidroergocriptina/análogos & derivados
Di-Hidroergocriptina/química
Di-Hidroergocriptina/metabolismo
Mesilatos Ergoloides/sangue
Mesilatos Ergoloides/metabolismo
Meia-Vida
Seres Humanos
Masculino
Meia-Idade
Estrutura Molecular
Peso Molecular
Ratos
Comprimidos
Espectrometria de Massas em Tandem
Vasodilatadores/administração & dosagem
Vasodilatadores/metabolismo
Vasodilatadores/farmacocinética
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Tablets); 0 (Vasodilator Agents); 0 (beta-dihydroergocryptine); 05D48LUM4Z (Dihydroergocristine); 67V3FSL2GL (Dihydroergocryptine); 8067-24-1 (Ergoloid Mesylates); IK4C1OC8NE (Dihydroergocornine)
[Em] Mês de entrada:0804
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:071018
[St] Status:MEDLINE


  6 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16707409
[Au] Autor:Lu WJ; Huang JD; Lai ML
[Ad] Endereço:Department of Neurology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
[Ti] Título:The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine.
[So] Source:J Clin Pharmacol;46(6):628-34, 2006 Jun.
[Is] ISSN:0091-2700
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Ticlopidine is sometimes coadministered with ergoloid mesylates or ginkgo biloba in clinical situations. Our objective was to examine the effect of ergoloid mesylates and ginkgo biloba on ticlopidine pharmacokinetics. Ticlopidine, ergoloid mesylates, and ginkgo biloba significantly inhibited the organic anion transporting polypeptide (OATP-B)-mediated uptake of [(3)H]-estrone-3-sulfate in a concentration-dependent manner. When ergoloid mesylates was coadministered with ticlopidine, the ticlopidine area under the plasma drug concentration-time profile (AUC) from 0 to 12 hours was decreased 30% and the peak plasma drug concentration (C(max)) was decreased 29%, compared with ticlopidine administration alone. There were no significant changes in the pharmacokinetic parameters of ticlopidine when it was coadministered with ginkgo biloba. In summary, ergoloid mesylates is a more potent inhibitor of OATP-B than is ginkgo biloba, and it can reduce the oral bioavailability of drugs transported by OATP-B. Ergoloid mesylates markedly decreased the AUC and C(max) of ticlopidine, probably by inhibiting the OATP-B-mediated uptake of ticlopidine during the intestinal absorption phase. The results support a new model of intestinal drug-drug interaction.
[Mh] Termos MeSH primário: Ginkgo biloba
Transportadores de Ânions Orgânicos/metabolismo
Inibidores da Agregação de Plaquetas/farmacocinética
Ticlopidina/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Linhagem Celular
Interações Medicamentosas
Mesilatos Ergoloides/farmacologia
Estrona/análogos & derivados
Estrona/metabolismo
Feminino
Seres Humanos
Absorção Intestinal/efeitos dos fármacos
Masculino
Preparações de Plantas/farmacologia
Inibidores da Agregação de Plaquetas/sangue
Ticlopidina/sangue
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Organic Anion Transporters); 0 (Plant Preparations); 0 (Platelet Aggregation Inhibitors); 0 (SLCO2B1 protein, human); 2DI9HA706A (Estrone); 8067-24-1 (Ergoloid Mesylates); OM90ZUW7M1 (Ticlopidine); QTL48N278K (estrone sulfate)
[Em] Mês de entrada:0611
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060519
[St] Status:MEDLINE


  7 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16449696
[Au] Autor:Werneke U; Turner T; Priebe S
[Ad] Endereço:Division of Psychiatry, Homerton University Hospital, East Wing, Homerton Row, London E9 6SR, UK. Ursula.Werneke@elcmht.nhs.uk
[Ti] Título:Complementary medicines in psychiatry: review of effectiveness and safety.
[So] Source:Br J Psychiatry;188:109-21, 2006 Feb.
[Is] ISSN:0007-1250
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed. AIMS: To review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions. METHOD: Electronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines. RESULTS: Potentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and s-adenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction. CONCLUSIONS: Systematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.
[Mh] Termos MeSH primário: Terapias Complementares/métodos
Transtornos Mentais/terapia
[Mh] Termos MeSH secundário: Antidepressivos/uso terapêutico
Antipsicóticos/uso terapêutico
Transtornos Cognitivos/tratamento farmacológico
Terapias Complementares/efeitos adversos
Demência/tratamento farmacológico
Discinesias/tratamento farmacológico
Mesilatos Ergoloides/uso terapêutico
Ácido Fólico/uso terapêutico
Seres Humanos
Hipnóticos e Sedativos/uso terapêutico
Nootrópicos/uso terapêutico
Fitoterapia/métodos
Preparações de Plantas/uso terapêutico
S-Adenosilmetionina/uso terapêutico
Selênio/uso terapêutico
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Antipsychotic Agents); 0 (Hypnotics and Sedatives); 0 (Nootropic Agents); 0 (Plant Preparations); 7LP2MPO46S (S-Adenosylmethionine); 8067-24-1 (Ergoloid Mesylates); 935E97BOY8 (Folic Acid); H6241UJ22B (Selenium)
[Em] Mês de entrada:0605
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060202
[St] Status:MEDLINE


  8 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15233578
[Au] Autor:Ogawa M
[Ad] Endereço:Department of Neurology, National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. ogawa-ma@ncnpmusashi.gr.jp
[Ti] Título:Pharmacological treatments of cerebellar ataxia.
[So] Source:Cerebellum;3(2):107-11, 2004.
[Is] ISSN:1473-4222
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The confirmed pharmacological treatment of cerebellar ataxia is still lacking. In a recent preliminary trial, we showed that D-cycloserine, a partial NMDA allosteric agonist, may relieve the symptoms. In this paper, major clinical trials to relieve ataxic symptoms are reviewed. Previous studies showed some efficacy of physostigmine in ataxic patients. However, physostigmine did not improve the ataxia in a recent double-blind crossover study. The replacement therapy of the deficient cholinergic system with choline or choline derivatives was tried in patients with Friedreich's ataxia and other ataxic patients, but the result was not definitive. A levorotatory form of hydroxytryptophan (a serotonin precursor), a serotoninergic 5-HT1A agonist, a serotoninergic 5-HT3 antagonist, and a serotonin reuptake inhibitor were also used for the therapy for ataxia. In a double-blind randomized study, buspirone, a 5-HT1A agonist was active in cerebellar ataxia, but the effect is partial and not major. The effects of the studies with the other serotoninergic drugs were not consistent. The effect of sulfamethoxazole-trimethoprim therapy in spinocerebellar ataxia type3/Machado-Joseph disease (MJD) was reported, although the therapy improved spasticity or rigidity, rather than ataxia. In contrast to previous studies, sulfamethoxazole-trimethoprim therapy in MJD had no effect in a 2001 double-blind crossover study. The thyrotropin-releasing hormone, D-cycloserine, and acetazolamide for SCA6 may have some efficacy. However, a well-designed double-blind crossover trial is needed to confirm the effect.
[Mh] Termos MeSH primário: Ataxia Cerebelar/tratamento farmacológico
Ciclosserina/uso terapêutico
Receptores de N-Metil-D-Aspartato/agonistas
[Mh] Termos MeSH secundário: Colina/análogos & derivados
Colina/uso terapêutico
Inibidores da Colinesterase/uso terapêutico
Ensaios Clínicos como Assunto
Mesilatos Ergoloides/uso terapêutico
Seres Humanos
Fisostigmina/uso terapêutico
Serotoninérgicos/uso terapêutico
Hormônio Liberador de Tireotropina/uso terapêutico
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Receptors, N-Methyl-D-Aspartate); 0 (Serotonin Agents); 5Y5F15120W (Thyrotropin-Releasing Hormone); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 8067-24-1 (Ergoloid Mesylates); 95IK5KI84Z (Cycloserine); 9U1VM840SP (Physostigmine); N91BDP6H0X (Choline); O60O0JB93O (acetergamine)
[Em] Mês de entrada:0408
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040706
[St] Status:MEDLINE


  9 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15126225
[Au] Autor:Belle SH; Zhang S; Czaja SJ; Burns R; Schulz R
[Ad] Endereço:Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA. Belle@edc.gsph-pitt.edu
[Ti] Título:Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project.
[So] Source:Am J Geriatr Psychiatry;12(3):250-7, 2004 May-Jun.
[Is] ISSN:1064-7481
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Aging populations show increased prevalence of cognitive impairment and dementia. Recent efficacy studies report on prescription medications and herbal preparations that affect cognitive functioning, but the prevalence and correlates of cognitive-enhancement (CE) medication use among community-dwelling older persons is not well studied. The authors examined the frequency and appropriateness of use, the importance of a family caregiver in medication decisions for dementia patients, and differences in access to medical care. METHODS: REACH is a multisite feasibility study of several approaches to reducing the negative impacts of caregiving on those living with a family member with dementia. Data on medication use by care-recipients were collected at baseline and 1 year later. RESULTS: At baseline, 31% of 1,222 care-recipients were using a CE medication. Factors independently related to CE use were age, education, functional status, and caregiver vigilance. Within 1 year, 14% started and 30% quit taking CE. Care-recipients more likely to be Starters had spouse-caregivers, more education, and fewer baseline ADL impairments. Quitters had more ADL deficits at baseline and became less able to perform ADL at follow-up than those who continued on CE. CONCLUSIONS: CE medication use among dementia patients with a family caregiver is relatively common, though there is substantial geographic variability. Our findings are mixed with respect to appropriate use of CE medications, suggesting areas for physician education. Our data indicate the importance of the caregiver in CE medication use and suggest that there may be disparities in access to healthcare among people with cognitive impairment.
[Mh] Termos MeSH primário: Doença de Alzheimer/tratamento farmacológico
Cuidadores
Transtornos Cognitivos/tratamento farmacológico
Fenilcarbamatos
Fitoterapia/estatística & dados numéricos
Plantas Medicinais
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carbamatos/uso terapêutico
Inibidores da Colinesterase/uso terapêutico
Sinergismo Farmacológico
Mesilatos Ergoloides/uso terapêutico
Seguimentos
Ginkgo biloba
Seres Humanos
Indanos/uso terapêutico
Meia-Idade
Panax
Piperidinas/uso terapêutico
Rivastigmina
Tacrina/uso terapêutico
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Carbamates); 0 (Cholinesterase Inhibitors); 0 (Indans); 0 (Phenylcarbamates); 0 (Piperidines); 0 (Vasodilator Agents); 4VX7YNB537 (Tacrine); 8067-24-1 (Ergoloid Mesylates); 8SSC91326P (donepezil); PKI06M3IW0 (Rivastigmine)
[Em] Mês de entrada:0408
[Cu] Atualização por classe:170607
[Lr] Data última revisão:
170607
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040506
[St] Status:MEDLINE


  10 / 500 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:14666760
[Au] Autor:Huang JS; Lin QC; Huang RZ
[Ad] Endereço:Affiliated Union Hospital of Fujian Medical University, Fuzhou 350001. hjsh0825@163.com
[Ti] Título:[Clinical study on effect of yuantong capsule in treating vascular dementia].
[So] Source:Zhongguo Zhong Xi Yi Jie He Za Zhi;23(11):815-8, 2003 Nov.
[Is] ISSN:1003-5370
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To observe the clinical effect of Yuantong Capsule (YTC) in treating vascular dementia (VD). METHODS: Eighty-three patients of VD were randomized on ratio of 2:1 into two groups, the 54 patients in the treated group were treated with YTC orally administered, 3 times a day, 1 capsule in each time. The remaining 29 patients in the control group were treated with Hydergine orally, 3 times a day, 2 mg in each time. The therapeutic course for both groups was 2 months. RESULTS: The therapeutic effect in the treated group was significantly better than that in the control group, significant difference (P < 0.05 or P < 0.01) was shown in comparison of the two groups in terms of the mini-mental state examination (MMSE) and activity of daily living (ADL) test, symptoms scoring, total effective rate, and laboratory indexes findings. CONCLUSION: The therapeutic effect of YTC in treating VD was obvious.
[Mh] Termos MeSH primário: Demência Vascular/tratamento farmacológico
Medicamentos de Ervas Chinesas/uso terapêutico
Mesilatos Ergoloides/uso terapêutico
Fitoterapia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Cápsulas
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Nootrópicos/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Capsules); 0 (Drugs, Chinese Herbal); 0 (Nootropic Agents); 8067-24-1 (Ergoloid Mesylates)
[Em] Mês de entrada:0401
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:031212
[St] Status:MEDLINE



página 1 de 50 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde